It has been confirmed by a number of large‐scale clinical trials that first‐generation TKI inhibitors, including gefitinib, erlotinib, and icotinib, significantly prolong progression‐free survival (PFS) in patients with EGFR‐sensitive mutations in NSCLC.4, 5, 6, 7. Here, EGFR is linked to non-small cell lung carcinoma.